Molecular Partners Valuation Multiples

Molecular Partners Overview

About Molecular Partners

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Founded

2004

HQ

Employees

159

Website

molecularpartners.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $2M

EBITDA: ($66M)

EV

$42M

Valuation Multiples

Multiples.vc

Start free trial

Molecular Partners Financials

Molecular Partners reported last 12-month revenue of $2M and negative EBITDA of ($66M).

In the same LTM period, Molecular Partners generated $2M in gross profit, ($66M) in EBITDA losses, and had net loss of ($71M).

Molecular Partners P&L

In the most recent fiscal year, Molecular Partners reported revenue of — and EBITDA of ($69M).

Molecular Partners expects next 12-month revenue of XXX and NTM EBITDA of XXX

Molecular Partners Stock Performance

Molecular Partners has current market cap of $156M, and enterprise value of $42M.

Molecular Partners' stock price is $4.18.

Molecular Partners Valuation Multiples

Molecular Partners trades at 20.1x EV/Revenue multiple, and (0.6x) EV/EBITDA.

Molecular Partners Financial Valuation Multiples

As of April 18, 2026, Molecular Partners has market cap of $156M and EV of $42M.

Equity research analysts estimate Molecular Partners' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Molecular Partners has a P/E ratio of (2.2x).

Molecular Partners Margins & Growth Rates

Molecular Partners' revenue in the last 12 month grew by 697%.

Molecular Partners' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.

Molecular Partners Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Molecular Partners M&A Activity

Molecular Partners acquired XXX companies to date.

Last acquisition by Molecular Partners was on XXXXXXXX, XXXXX. Molecular Partners acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Molecular Partners Investment Activity

Molecular Partners invested in XXX companies to date.

Molecular Partners made its latest investment on XXXXXXXX, XXXXX. Molecular Partners invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).